128 results
8-K
EX-99.1
ADAP
Adaptimmune Therapeutics Plc
6 Mar 24
Adaptimmune Reports Q4 /Full Year 2023 Financial Results and Business Updates
7:05am
income for the collaboration being recognized as revenue in March 2023.
Research and development (R&D) expenses: R&D expenses for the three months … engaged in research and development following the restructuring completed in the first quarter of 2023, decreases in subcontracted expenditures
8-K
EX-10.1
ADAP
Adaptimmune Therapeutics Plc
27 Feb 24
Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company’s Sarcoma Franchise
8:13am
, or fixation in a tangible medium of expression of such Work Product, to the Group’s business or actual or demonstrably anticipated research, development … president, senior vice president) or above or equivalent or (ii) research and development staff, manufacturing staff or equivalent or (iii) key personnel
8-K
EX-99.1
tm2k4 zpup1rsptt51k
8 Nov 23
Adaptimmune Reports Third Quarter Financial Results and Business Update
7:37am
8-K/A
EX-99.3
xvivb44t
10 Aug 23
Financial Statements and Exhibits
4:05pm
8-K
EX-99.1
u1x355
9 Aug 23
Adaptimmune Reports Second Quarter Financial Results and Business Update
7:42am
8-K
EX-99.1
b13v 3nsc8l
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
425
aoulyxsm
30 May 23
Business combination disclosure
4:21pm
8-K
h3ikfb7l5k6k
30 May 23
Submission of Matters to a Vote of Security Holders
4:18pm
425
8nej7a
22 May 23
Business combination disclosure
7:01am
8-K
3fh2fe0j
22 May 23
Other Events
6:59am
8-K
EX-99.1
9n7otk rri
12 May 23
Adaptimmune Reports First Quarter Financial Results and Business Update
7:36am
424B3
kq74b1gi u05irlrgum2
20 Apr 23
Prospectus supplement
4:32pm
S-4/A
0ee81
18 Apr 23
Registration of securities issued in business combination transactions (amended)
4:01pm